Project Velocity Inc. (PVI) and NovaSpark Ventures have officially formed a strategic partnership after a year of working together to support product launches for pharmaceutical companies, especially in the area of rare diseases. The two companies are combining their strengths in planning, strategy, market knowledge, and execution to help biotech and pharma companies launch their products more quickly and effectively.
Over the past year, they operated on twelve projects, helping two major They helped pharmaceutical clients launch four rare disease products. By working together, they turned ideas into quick actions, speeding up the process from planning to market entry. This teamwork made the launches faster and more efficient.
Going forward, PVI and NovaSpark will invest in tools, strategies, and leadership services to help biotech and pharma companies reduce the time it takes to get their products to market. They will work closely with teams to create strategies that improve prelaunch readiness and performance, aiming to turn good product launches into highly successful ones.
The focus of the partnership will be on major areas to speed up product launches, including:
- Developing strategies based on market insights
- Coordinating teams and planning for launch readiness
- Ensuring strong communication and alignment across teams
- Efficient execution and rapid implementation of plans
With expertise in rare diseases and product launches, PVI operates closely with client teams to drive clear results. Since 2022, PVI has completed over 160 projects across the U.S., Europe, and global markets.
Executive Statement
According to Jennifer Johnson, Founder and CEO of PVI., they have already seen the power of their teams when they join forces. Formalizing this alliance was the next natural step in their collaboration. Together, they bring sharper insight, faster integration, and the executional rigor required for leaders preparing to launch in competitive and dynamic markets.
